Alaunos Therapeutics, Inc.
TCRT · XNASCIK 1107421fmd_1MSW0F4TCNH6MSWPSGXAB5B3QEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2003 to Jun 30, 2026, 73 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 7 | 16 | 0 | – | 0 | 0 | 3 | 0 | 0 | 0 |
| Research and development | 158 | 45 | 34 | 38 | 53 | 50 | 25 | 16 | 0 | 1 |
| Total operating expenses | – | 60 | 54 | 58 | 80 | 78 | 38 | 34 | 5 | 4 |
| Operating income | (165) | (53) | (54) | (58) | (80) | (78) | (35) | (34) | (5) | (4) |
| Interest expense | – | – | – | – | – | 1 | 3 | 2 | 0 | – |
| Other non-operating income (expense) | 0 | 0 | 1 | 1 | 0 | (1) | (3) | (1) | 0 | 0 |
| Income tax expense | – | – | – | – | – | – | – | – | – | 0 |
| Net income | (165) | (54) | (53) | (118) | (80) | (79) | (38) | (5) | (5) | (4) |
| Net income to common shareholders | (172) | (73) | 137 | (118) | (80) | (79) | – | – | (5) | (4) |